Roche Diagnostics today announces that it has completed its acquisition of BioVeris. Roche signed the merger agreement with BioVeris for approximately $600 million on April 4, 2007.
This means Roche Diagnostics now owns the patents for Electrochemiluminescence (ECL) technology and can expand its immunochemistry business from the human diagnostics field into new market segments such as life sciences research, life science development, patient self-testing, veterinary testing, drug discovery, drug development and clinical trials.
"We are excited to be able to offer ECL technology to existing and new customers for these expanded uses. This is a highly innovative technology that our customers and their patients will certainly benefit from," said Andy Thomson, Senior Vice President, Centralized Diagnostics, Roche Diagnostics Corporation.
Today, Roche is a leader in immunochemistry, driven by its highly successful Elecsys(R) immunochemistry product line, the fastest growing portfolio of Roche Diagnostics' lab diagnostics business.
Source: PR Newswire